BRPI0809088A2 - Pirimidodiazepinas substituídas úteis como inibidoras de plk1 - Google Patents

Pirimidodiazepinas substituídas úteis como inibidoras de plk1 Download PDF

Info

Publication number
BRPI0809088A2
BRPI0809088A2 BRPI0809088-2A BRPI0809088A BRPI0809088A2 BR PI0809088 A2 BRPI0809088 A2 BR PI0809088A2 BR PI0809088 A BRPI0809088 A BR PI0809088A BR PI0809088 A2 BRPI0809088 A2 BR PI0809088A2
Authority
BR
Brazil
Prior art keywords
methyl
mol
tetrahydro
diazepin
cyclopentyl
Prior art date
Application number
BRPI0809088-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0809088(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0809088A2 publication Critical patent/BRPI0809088A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0809088-2A 2007-03-22 2008-03-11 Pirimidodiazepinas substituídas úteis como inibidoras de plk1 BRPI0809088A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0809088A2 true BRPI0809088A2 (pt) 2014-09-09

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809088-2A BRPI0809088A2 (pt) 2007-03-22 2008-03-11 Pirimidodiazepinas substituídas úteis como inibidoras de plk1

Country Status (23)

Country Link
US (1) US7517873B2 (OSRAM)
EP (1) EP2139892B1 (OSRAM)
JP (1) JP5087640B2 (OSRAM)
KR (1) KR101157848B1 (OSRAM)
CN (2) CN101636399B (OSRAM)
AR (1) AR065794A1 (OSRAM)
AT (1) ATE524472T1 (OSRAM)
AU (1) AU2008228303B2 (OSRAM)
BR (1) BRPI0809088A2 (OSRAM)
CA (1) CA2680757A1 (OSRAM)
CL (1) CL2008000785A1 (OSRAM)
CY (1) CY1112102T1 (OSRAM)
DK (1) DK2139892T3 (OSRAM)
ES (1) ES2371832T3 (OSRAM)
HR (1) HRP20110807T1 (OSRAM)
IL (1) IL200617A (OSRAM)
MX (1) MX2009010034A (OSRAM)
PE (1) PE20120495A1 (OSRAM)
PL (1) PL2139892T3 (OSRAM)
PT (1) PT2139892E (OSRAM)
SI (1) SI2139892T1 (OSRAM)
TW (1) TWI363629B (OSRAM)
WO (1) WO2008113711A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
MX2010003249A (es) * 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9676792B2 (en) * 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN109311901A (zh) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3792002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
HRP20040213A2 (en) * 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
DE602007008837D1 (de) * 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ES2371832T3 (es) 2012-01-10
CN102746175B (zh) 2014-01-15
DK2139892T3 (da) 2011-12-12
US7517873B2 (en) 2009-04-14
JP5087640B2 (ja) 2012-12-05
HK1139936A1 (en) 2010-09-30
KR101157848B1 (ko) 2012-07-11
HRP20110807T1 (hr) 2011-12-31
TW200843781A (en) 2008-11-16
ATE524472T1 (de) 2011-09-15
IL200617A0 (en) 2010-05-17
MX2009010034A (es) 2009-10-12
PL2139892T3 (pl) 2012-03-30
EP2139892B1 (en) 2011-09-14
PT2139892E (pt) 2011-11-21
JP2010521514A (ja) 2010-06-24
AU2008228303B2 (en) 2012-04-19
CL2008000785A1 (es) 2009-03-27
SI2139892T1 (sl) 2011-12-30
EP2139892A1 (en) 2010-01-06
CA2680757A1 (en) 2008-09-25
PE20120495A1 (es) 2012-05-12
KR20090119913A (ko) 2009-11-20
TWI363629B (en) 2012-05-11
CY1112102T1 (el) 2015-11-04
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
US20080234255A1 (en) 2008-09-25
AR065794A1 (es) 2009-07-01
AU2008228303A1 (en) 2008-09-25
CN101636399B (zh) 2012-04-18
WO2008113711A1 (en) 2008-09-25
IL200617A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
BRPI0809088A2 (pt) Pirimidodiazepinas substituídas úteis como inibidoras de plk1
AU2016203348B2 (en) Macrocyclic compounds as trk kinase inhibitors
ES2765671T3 (es) Imidazotriazinonas como inhibidores de PDE1
ES2951427T3 (es) Macrociclo que contiene aminopirazol y pirimidina y composición farmacéutica y uso del mismo
CA3033020A1 (en) Fused bicyclic inhibitors of menin-mll interaction
ES2999539T3 (en) 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis
EA028890B1 (ru) Гетероциклиламины как ингибиторы pi3k
JP2011506524A (ja) スピロインドリノン誘導体
HUE027771T2 (en) 1-Heterocyclyl-1,5-dihydro-pyrazolo [3,4-D] pyrimidin-4-one and their use as PDE9A modulators
MX2012004289A (es) Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
RS64800B1 (sr) Imidazo[4,5-b]piridinska jedinjenja i njihove farmaceutske kompozicije za lečenje inflamatornih poremećaja
ES2706475T3 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
EP2886540B1 (en) Bicyclic substituted pyrimidine compounds
JP2023538393A (ja) 線維症の処置のためのtlr9の阻害剤としてのイミダゾ[1,2-a]ピリジンおよび[1,2,4]トリアゾロ[1,5-a]ピリジン誘導体
ES2346147T3 (es) Derivados de oxa-diaza-espiro-(5.5)-undecanona sustituidos y su uso como antagonistas de las neuroquininas.
WO2025002179A1 (en) Heterotricyclic n-[1-(2-benzofuranyl)-methyl]-urea derivatives as pi3k alpha inhibitors for the treatment of cancer
JP5078869B2 (ja) ニューロキニン(nk1)拮抗物質としてのジアザ−スピロ−[4.4]−ノナン誘導体
CN116354932A (zh) 嘧啶衍生物及其制备方法和用途
CN116444497B (zh) 一类哒嗪酮类化合物、制备及其应用
CN120441546A (zh) 一种cdk抑制剂化合物
WO2025042769A1 (en) Compounds and methods for inhibiting poly(adp-ribose) polymerases
CN117659007A (zh) 一种吡嗪酮衍生物及其在医药上的应用
EA050655B1 (ru) Замещенные бициклические соединения, пригодные для применения в качестве ингибиторов tlr9
CN119731160A (zh) 依莫帕米结合蛋白抑制剂及其用途
CN105579459B (zh) 四并环类间变性淋巴瘤激酶抑制剂

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25E Requested change of name of applicant rejected

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)